Objective: One of the greatest challenges of achieving successful surgical outcomes in patients with epilepsy is the ability to properly localize the seizure onset zone (SOZ). Many techniques exist for localizing the SOZ, including intracranial electroencephalography, magnetoencephalography, and stereoelectroencephalography. Recently, resting-state functional magnetic resonance imaging (rs-fMRI) in conjunction with independent component analysis (ICA) has been utilized for presurgical planning of SOZ resection, with varying results. In this meta-analysis, we analyze the current role of rs-fMRI in identifying the SOZ for presurgical planning for patients with drug-resistant epilepsy. Specifically, we seek to demonstrate its current effectiveness compared to other methods of SOZ localization. Methods: A literature review was conducted using the PubMed, MEDLINE, and Embase databases up to May of 2020. A total of 253 articles were screened, and seven studies were chosen for analysis. Each study was analyzed for SOZ localization by ground truth, SOZ localization by rs-fMRI with ICA, principal component analysis, or intrinsic connectivity contrast, and outcomes of surgery. A meta-analysis was performed to analyze how ground truth compares to rs-fMRI in SOZ localization. Results: The odds ratio comparing ground truth to rs-fMRI was 2.63 (95% confidence interval = 0.66-10.56). Average concordance of rs-fMRI SOZ localization compared with ground truth localization across studies was 71.3%. Significance: In the hunt for less invasive presurgical planning for epilepsy surgery, rs-fMRI with ICA provides a promising avenue for future standard practice. Our preliminary results show no significant difference in surgical outcomes between traditional standards of SOZ localization and rs-fMRI with ICA. We believe that rs-fMRI could be a step forward in this search. Further investigation comparing rs-fMRI to traditional methods of SOZ localization should be conducted, with the hope of moving toward relying solely on noninvasive screening methods.
This paper presents a photoacoustic non-destructive evaluation (pNDE) system with an ultrahigh resolution for the detection of multi-scale damage in carbon fiber-reinforced plastic (CFRP) composites. The pNDE system consists of three main components: a picosecond pulsed laser-based ultrasonic actuator, an ultrasound receiver, and a data acquisition/computing subsystem. During the operation, high-frequency ultrasound is generated by pulsed laser and recorded by an ultrasound receiver. By implementing a two-dimensional back projection algorithm, pNDE images can be reconstructed from the recorded ultrasound signals to represent the embedded damage. Both potential macroscopic and microscopic damages, such as surface notches and delamination in CFRP, can be identified by examining the reconstructed pNDE images. Three ultrasonic presentation modes including A-scan, B-scan, and C-scan are employed to analyze the recorded signals for the representation of the detected micro-scale damage in two-dimensional and three-dimensional images with a high spatial resolution of up to 60 µm. Macro-scale delamination and transverse ply cracks are clearly visualized, identifying the edges of the damaged area. The results of the study demonstrate that the developed pNDE system provides a non-destructive and robust approach for multi-scale damage detection in composite materials.
The response assessment in neuro-oncology (RANO) criteria have been the gold standard for monoitoring treatment response in glioblastoma (GBM) and differentiating tumor progression from pseudoprogression. While the RANO criteria have played a key role in detecting early tumor progression, their ability to identify pseudoprogression is limited by post-treatment damage to the blood-brain barrier (BBB), which often leads to contrast-enhancement on MRI and correlates poorly to tumor status. Amino acid positron emission tomography (AA PET) is a rapidly growing imaging modality in neuro-oncology. While contrast-enhanced MRI relies on leaky vascularity or a compromised BBB for delivery of contrast agents, amino acid tracers can cross the BBB, making AA PET particularly well-suited for monitoring treatment response and diagnosing pseudoprogression. The authors performed a systematic review of PubMed, MEDLINE, and Embase through December 2021 with the search terms “temozolomide” OR “Temodar,” “glioma” OR “glioblastoma,” “PET,” and “amino acid.” There were 19 studies meeting inclusion criteria. Thirteen studies utilized [ 18F]FET, five utilized [ 11C]MET, and one utilized both. All studies used static AA PET parameters to evaluate TMZ treatment in glioma patients, with nine using dynamic tracer parameters in addition. Throughout these studies, AA PET demonstrated utility in TMZ treatment monitoring and predicting patient survival.
Objective: Proton therapy as the next generation radiation-based cancer therapy offers dominant advantages over conventional radiation therapy due to the utilization of the Bragg peak; however, range uncertainty in beam delivery substantially mitigates the advantages of proton therapy. This work reports using protoacoustic measurements to determine the location of proton Bragg peak deposition within a water phantom in real time during beam delivery. Approach: In protoacoustics, proton beams have a definitive range, depositing a majority of the dose at the Bragg peak; this dose is then converted to heat. The resulting thermoelastic expansion generates a 3D acoustic wave, which can be detected by acoustic detectors to localize the Bragg peak. Main results: Protoacoustic measurements were performed with a synchrocyclotron proton machine over the exhaustive energy range from 45.5MeV to 227.15MeV in clinic. It was found that the amplitude of the acoustic waves is proportional to proton dose deposition, and therefore encodes dosimetric information. With the guidance of protoacoustics, each individual proton beam (7pC/pulse) can be directly visualized with sub-millimeter (<0.7 mm) resolution using single beam pulse for the first time. Significance: The ability to localize the Bragg peak in real-time and obtain acoustic signals proportional to dose within tumors could enable precision proton therapy and hope to progress towards in-vivo measurements.
Cancer has been and continues to be a leading cause of death globally. More than half of all cancer patients undergo ionizing radiation therapy and dosimetry is crucial to the success and improvement of these treatments - ensuring that an accurate radiation dose is delivered to the target location. Despite widespread clinical use, the delivered dose can only be planned and verified via simulations with phantoms, and an in-tumor, on-line dose verification is still unavailable after more than one-hundred years of clinical application. X-ray-induced acoustic computed tomography (XACT) has recently shown the potential for imaging the delivered radiation dose within the tumor. Prior XACT imaging systems require tens of averages to achieve reasonable images. Here, we demonstrate that our XACT signals can be detected for each individual X-ray pulse (4µs) with sub-mGy sensitivity from a clinical linear accelerator during radiotherapy. Single-pulse XACT imaging holds great potential for personalized precision radiotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.